Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Posaconazole

FDA-approved product (suspension, oral), marketed as Noxafil, Noxafil Powdermix Kit, Posaconazole.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Posaconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidiasis
  • Coccidioidomycosis
  • Fungal infectious disease
  • Neutropenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC04; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA72.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Posaconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Posaconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • King's Invasive Aspergillosis Study II

    NCT02875743 · start 2016-12-07

    Registered record
    Registry ID
    NCT02875743
    Conditions
    Aplastic Anemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Bone Marrow Transplantation
    Interventions
    Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-12-07
    Completion
    2019-10-31
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAplastic Anemia; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Bone Marrow Transplantation
    InterventionPosaconazole
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)

    NCT02387983 · start 2015-05-06

    Registered record
    Registry ID
    NCT02387983
    Conditions
    Fungal Infection
    Interventions
    Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-05-06
    Completion
    2016-05-02
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infection
    InterventionPosaconazole
    PhasePhase 1
    Registry statusCompleted

  • Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

    NCT02203773 · start 2014-10-06

    Registered record
    Registry ID
    NCT02203773
    Conditions
    Acute Myelogenous Leukemia; Myelogenous Leukemia; Treatment Naive AML
    Interventions
    Posaconazole; ABT-199; Decitabine; Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2014-10-06
    Completion
    2022-06-16
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myelogenous Leukemia; Myelogenous Leukemia; Treatment Naive AML
    InterventionPosaconazole; ABT-199; Decitabine; Azacitidine
    PhasePhase 1
    Registry statusTerminated

  • A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers

    NCT01984229 · start 2013-12

    Registered record
    Registry ID
    NCT01984229
    Conditions
    Healthy Volunteer
    Interventions
    Alectinib; Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-12
    Completion
    2014-03
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionAlectinib; Posaconazole
    PhasePhase 1
    Registry statusCompleted

  • Posaconazole as Salvage Therapy for Aspergillus Pulmonary Infection.

    NCT02020213 · start 2013-12

    Registered record
    Registry ID
    NCT02020213
    Conditions
    Clinical Infection
    Interventions
    Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2013-12
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Infection
    InterventionPosaconazole
    PhasePhase 4
    Registry statusWithdrawn

  • A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)

    NCT01782131 · start 2013-09-25

    Registered record
    Registry ID
    NCT01782131
    Conditions
    Fungal Infections; Invasive Pulmonary Aspergillosis
    Interventions
    Posaconazole; Voriconazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-25
    Completion
    2019-09-10
    Enrolment
    585

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infections; Invasive Pulmonary Aspergillosis
    InterventionPosaconazole; Voriconazole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors

    NCT01901172 · start 2013-08

    Registered record
    Registry ID
    NCT01901172
    Conditions
    Neoplasms
    Interventions
    RO5503781; RO5503781; RO5503781; RO5503781; posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08
    Completion
    2015-06
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionRO5503781; RO5503781; RO5503781; RO5503781 +1 more
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic Study in Patients Receiving Posaconazole Therapy in Taiwan

    NCT02217761 · start 2012-03

    Registered record
    Registry ID
    NCT02217761
    Conditions
    Pharmacokinetics; Posaconazole
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2012-03
    Completion
    2017-07
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics; Posaconazole
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area

    NCT02372357 · start 2012-02

    Registered record
    Registry ID
    NCT02372357
    Conditions
    Hematological Malignancy
    Interventions
    Posaconazole prophylaxis 120 mg/m² tid; Blood sampling
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-02
    Completion
    2014-10
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Malignancy
    InterventionPosaconazole prophylaxis 120 mg/m² tid; Blood sampling
    PhasePhase 4
    Registry statusCompleted

  • A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)

    NCT01377480 · start 2011-07-06

    Registered record
    Registry ID
    NCT01377480
    Conditions
    Chagas Disease
    Interventions
    Posaconazole; Placebo for posaconazole; Benznidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-07-06
    Completion
    2015-01-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease
    InterventionPosaconazole; Placebo for posaconazole; Benznidazole
    PhasePhase 2
    Registry statusCompleted

  • Effects of Posaconazole and Voriconazole on the Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine

    NCT01367808 · start 2011-02

    Registered record
    Registry ID
    NCT01367808
    Conditions
    Pharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine
    Interventions
    Placebo; vorikonazole; posakonazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02
    Completion
    2011-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics and Pharmacodynamics of Sublingual Buprenorphine
    InterventionPlacebo; vorikonazole; posakonazole
    PhasePhase 1
    Registry statusCompleted

  • Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole

    NCT01162967 · start 2010-09

    Registered record
    Registry ID
    NCT01162967
    Conditions
    Chagas Disease
    Interventions
    Benznidazole; Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-09
    Completion
    2013-03
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease
    InterventionBenznidazole; Posaconazole
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia

    NCT00936117 · start 2009-09

    Registered record
    Registry ID
    NCT00936117
    Conditions
    Leukemia; Fungal Infection
    Interventions
    Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-09
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Fungal Infection
    InterventionPosaconazole
    PhasePhase 2
    Registry statusCompleted

  • Invasives Aspergillosis in Acute Myeloid Leukemia

    NCT02900430 · start 2009-01

    Registered record
    Registry ID
    NCT02900430
    Conditions
    Acute Myeloid Leukemia; Invasive Aspergillosis
    Interventions
    Patients without antifungal prophylaxis; Patients with antifungal prophylaxis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-01
    Completion
    2015-12
    Enrolment
    246

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Invasive Aspergillosis
    InterventionPatients without antifungal prophylaxis; Patients with antifungal prophylaxis
    PhaseNot recorded
    Registry statusCompleted

  • Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)

    NCT00811642 · start 2008-11

    Registered record
    Registry ID
    NCT00811642
    Conditions
    Fungal Infection
    Interventions
    Posaconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-11
    Completion
    2010-03
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infection
    InterventionPosaconazole
    PhasePhase 3
    Registry statusCompleted